Abbott Laboratories
Search results
employees turning possibilities into reality for people and patients. Our products are approved in individual countries for specific uses and the information provided is governed by local regulations. Product availability, name and indicated use may vary by country. Please contact your local AbbVie office to learn more about products available ...
- Pipeline
CLBR001 is a Chimeric antigen receptor T (CAR-T) cell...
- Pharmaceutical Research & Development
AbbVie pharmaceuticals combines advanced science with...
- Pipeline
AbbVie | Pharmaceutical Research & Development. Inventing the Future of Medicine. By investing in groundbreaking technologies, we’re on a mission to deliver better solutions to patients. Learn more. Pipeline. Advancing medicines with strong clinical performance in areas of great need. Focus Areas.
It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis . It developed Skyrizi ($7.8 billion in 2023 revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases.
At AbbVie, what we do is as important as the way we do it. We go beyond developing medicines, using our resources to improve approaches to health and society in general. We are committed to: Improve health outcomes by advancing patient health and wellbeing through our focus on innovation.
AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.
Our Products. A Portfolio of Medicines. We aim to develop innovative therapies for health conditions where there is significant need. Our medicines are approved in individual countries for different uses around the globe. Explore.
CLBR001 is a Chimeric antigen receptor T (CAR-T) cell product that comprises the patient’s T cells and a novel “switchable” chimeric antigen receptor (sCAR-T). SWI019 is an Antibody Fab-based biologic, called the “switch”, which targets the B cell antigen CD19.
